Sinopep

Executive Summary

Sinopep is a Chinese biopharmaceutical company specializing in peptide-based therapeutics and complex generics, with a strong focus on metabolic disorders such as diabetes and obesity. Founded in 2001 and headquartered in Nanjing, the company operates integrated facilities for peptide API synthesis and finished drug production, positioning it as a key player in the rapidly growing GLP-1 receptor agonist market. As a publicly traded, commercial-stage company with 500–1000 employees, Sinopep has established capabilities to develop and manufacture both branded and generic peptide drugs, targeting the large and expanding patient populations in China and globally. The company's strategic emphasis on complex generic peptides and novel metabolic therapies, combined with its vertically integrated manufacturing, provides cost advantages and supply chain reliability amid rising demand for obesity and diabetes treatments. Looking ahead, Sinopep is poised to capitalize on its pipeline of peptide-based candidates, including potential next-generation GLP-1 analogs and combination therapies. The company is expected to benefit from the Chinese government's support for domestic innovation in chronic disease management and the increasing adoption of injectable peptides for weight loss and glycemic control. With a robust manufacturing infrastructure and a track record of regulatory approvals, Sinopep is well-positioned to capture market share in both the domestic and international peptide therapeutic markets. Key near-term events include clinical data readouts and potential regulatory decisions that could drive significant value.

Upcoming Catalysts (preview)

• Q4 2026NMPA Approval for Novel GLP-1 Analog for Diabetes70% success
• Q3 2026Phase 3 Top-Line Data for Obesity Peptide Candidate65% success
• Q2 2026Ex-China Licensing or Partnership Agreement50% success